MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- DR. LAL PATHLABS (hospital & healthcare services)
- Latest 8 Quarter Result
Dr. Lal Pathlabs Quarterly Results (DRLP)
Here are the latest quarterly results of Dr. Lal Pathlabs. For more details, see the Dr. Lal Pathlabs financial fact sheet and Dr. Lal Pathlabs share price and chart. For a sector overview, read our pharmaceuticals sector report.
Dr. Lal Pathlabs Quarterly Results
| No. of Mths Qtr. Ending |
3
Sep-19* |
3
Dec-19* |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
3
Mar-21* |
3
Jun-21* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 3,656 | 3,279 | 3,017 | 2,660 | 4,319 | 4,524 | 4,310 | 6,066 | |
| Other income | Rs m | 148 | 138 | 120 | 114 | 129 | 135 | 135 | 141 | |
| Turnover | Rs m | 3,804 | 3,417 | 3,137 | 2,774 | 4,448 | 4,659 | 4,445 | 6,207 | |
| Expenses | Rs m | 2,567 | 2,456 | 2,444 | 2,177 | 3,047 | 3,136 | 3,090 | 4,176 | |
| Gross profit | Rs m | 1,089 | 823 | 573 | 483 | 1,272 | 1,388 | 1,220 | 1,890 | |
| Depreciation | Rs m | 177 | 188 | 200 | 179 | 195 | 195 | 203 | 192 | |
| Interest | Rs m | 37 | 39 | 39 | 37 | 40 | 39 | 44 | 46 | |
| Profit before tax | Rs m | 1,023 | 734 | 454 | 381 | 1,166 | 1,289 | 1,108 | 1,793 | |
| Tax | Rs m | 213 | 185 | 128 | 97 | 295 | 330 | 257 | 456 | |
| Profit after tax | Rs m | 810 | 549 | 326 | 284 | 871 | 959 | 851 | 1,337 | |
| Gross profit margin | % | 29.8 | 25.1 | 19.0 | 18.2 | 29.5 | 30.7 | 28.3 | 31.2 | |
| Effective tax rate | % | 20.8 | 25.2 | 28.2 | 25.5 | 25.3 | 25.6 | 23.2 | 25.4 | |
| Net profit margin | % | 22.2 | 16.7 | 10.8 | 10.7 | 20.2 | 21.2 | 19.7 | 22.0 | |
| Diluted EPS | Rs | 9.7 | 6.6 | 3.9 | 3.4 | 10.5 | 11.5 | 10.2 | 16.0 | |
| Diluted EPS (TTM) | Rs | NA | 29.1 | 27.3 | 23.6 | 24.4 | 29.3 | 35.6 | 48.2 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Dr. Lal Pathlabs 1QFY22 Result Performance Review
More Hospital & Healthcare Services Company Quarterly Results: BIOFIL CHEMICALS ASTER DM HEALTHCARE SWAGRUHA INFRA DIVIS LABORATORIES ARTEMIS MEDICARE SERVICES
Compare DR. LAL PATHLABS With: BIOFIL CHEMICALS ASTER DM HEALTHCARE SWAGRUHA INFRA DIVIS LABORATORIES ARTEMIS MEDICARE SERVICES
Today's Market
Sensex Ends 123 Points Higher; Bharti Airtel and Eicher Motors Among Top Nifty Gainers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended higher.
Views on news
DR. LAL PATHLABS Announces Quarterly Results (1QFY22); Net Profit Up 370.8% (Quarterly Result Update)
Aug 3, 2021 | Updated on Aug 3, 2021For the quarter ended June 2021, DR. LAL PATHLABS has posted a net profit of Rs 1 bn (up 370.8% YoY). Sales on the other hand came in at Rs 6 bn (up 128.0% YoY). Read on for a complete analysis of DR. LAL PATHLABS's quarterly results.
Krsnaa Diagnostics IPO Opens Tomorrow: Key Points to Consider (Views On News)
Aug 3, 2021Krsnaa Diagnostics grey market premium is at around Rs 440 from its issue price of Rs 933-954.
Windlas Biotech IPO to Hit the Market on 4 August. Key Points to Know (Views On News)
Jul 31, 2021Windlas Biotech IPO to open for subscription next week. Price band fixed at Rs 448-460.
Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates (Views On News)
Jul 30, 2021Here's a rundown on Sun Pharma's June quarter results.
Glenmark Life Sciences IPO Opens Tomorrow: Few Points to Know Before Applying (Views On News)
Jul 26, 2021All you need to know about the IPO of Glenmark Life Sciences.
More Views on NewsMost Popular
These Stocks Are Ready to Zoom (Fast Profits Daily)
Aug 3, 2021These stocks are the best from a traders point of view.
A Trading Hack to Multiply Profits (Fast Profits Daily)
Jul 23, 2021Use this trading hack and get a big boost in your trading profits.
How to Pick Momentum Stocks (Fast Profits Daily)
Jul 26, 2021Use my trading momentum strategy to increase your trading profits.
Devyani International IPO: Key Points to Consider (Views On News)
Jul 31, 2021Its raining IPOs as 4 public issues open next week on the same day. Which one will you subscribe to?
A Rare Opportunity for Long-Term Investors Amid the Rout in China's Tech Stocks (Profit Hunter)
Jul 29, 2021The epicentre of a tech-bubble led market crash in 2021 is closer than you think.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
DR. LAL PATHLABS SHARE PRICE
Aug 5, 2021 (Close)
TRACK DR. LAL PATHLABS
- Track your investment in DR. LAL PATHLABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DR. LAL PATHLABS
DR. LAL PATHLABS 5-YR ANALYSIS
COMPARE DR. LAL PATHLABS WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
FOLLOW
APP
EQUITYMASTER SUPPORTS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.